## The disclosure: institutional access at real scale (not “nice-to-have”) Scienture says it has formalized multiple Group Purchasing Organization (GPO) agreements for REZENOPY™ (naloxone HCl) Nasal Spray 10 mg that provide access to **more than 5,000** U.S. healthcare institutions, representing potential penetration of **~60% of the U.S. institutional market**, and expanding reach across hospitals/clinics/nursing homes as well as first responders, EMS providers, and rehabilitation centers. ["GPO agreements"](https://www.manilatimes.net/2026/03/11/tmt-newswire/globenewswire/scienture-broadens-commercial-access-for-rezenopy-highest-dose-fda-approved-naloxone-nasal-spray-through-gpo-agreements-reaching-over-5000-us-institutions/2297857) ["more than 5000"](https://www.manilatimes.net/2026/03/11/tmt-newswire/globenewswire/scienture-broadens-commercial-access-for-rezenopy-highest-dose-fda-approved-naloxone-nasal-spray-through-gpo-agreements-reaching-over-5000-us-institutions/2297857) ["roughly 60%"](https://www.manilatimes.net/2026/03/11/tmt-newswire/globenewswire/scienture-broadens-commercial-access-for-rezenopy-highest-dose-fda-approved-naloxone-nasal-spray-through-gpo-agreements-reaching-over-5000-us-institutions/2297857) ## The “between-the-lines” alpha: procurement gravity beats awareness marketing The real signal here is **channel control**. In institutional pharma, getting into the purchasing lane is often the gating factor; a product can have clinical rationale and still stall if it’s not in the contracting rails buyers actually use. By locking in GPO access *before* broad-scale adoption, Scienture is effectively attempting to convert REZENOPY from a “product story” into a **procurement default** across a large swath of the institutional landscape. ["Institutional procurement channels are a key driver"](https://www.manilatimes.net/2026/03/11/tmt-newswire/globenewswire/scienture-broadens-commercial-access-for-rezenopy-highest-dose-fda-approved-naloxone-nasal-spray-through-gpo-agreements-reaching-over-5000-us-institutions/2297857) ## Why this matters specifically for REZENOPY: a high-dose product positioned for hard cases The company is explicitly positioning REZENOPY as the **highest-dose FDA-approved naloxone nasal spray**, and ties the institutional push to settings where “failure is not an option” (EMS, hospitals, rehab)—i.e., environments that may value higher-dose rescue options for potent opioids. ["highest-dose FDA-approved"](https://www.manilatimes.net/2026/03/11/tmt-newswire/globenewswire/scienture-broadens-commercial-access-for-rezenopy-highest-dose-fda-approved-naloxone-nasal-spray-through-gpo-agreements-reaching-over-5000-us-institutions/2297857) ["highest dosage"](https://www.manilatimes.net/2026/03/11/tmt-newswire/globenewswire/scienture-broadens-commercial-access-for-rezenopy-highest-dose-fda-approved-naloxone-nasal-spray-through-gpo-agreements-reaching-over-5000-us-institutions/2297857) ## The de-risking angle from filings: rights + supply chain + commercial control Importantly, this institutional expansion sits on top of a structure Scienture already disclosed: an **exclusive** U.S. commercialization arrangement where Scienture has the right and license to commercialize REZENOPY in the U.S. and intends to price, launch, promote, market, and distribute the product. ["exclusive... right and license"](0001493152-25-009737|0) ["price, launch, promote"](0001493152-25-009737|0) Just as critical, the earlier disclosure also frames a cleaner execution model: Kindeva (via Summit Biosciences) manufactures and commercially supplies REZENOPY, while Scienture owns the NDA and runs sales/marketing/distribution through its commercial infrastructure—i.e., Scienture is trying to scale demand through contracting and channel access while leaning on an established partner for supply. ["manufacture and commercially supply"](0001493152-25-009737|2) ["own the new drug application"](0001493152-25-009737|2) ["sales, marketing and distribution"](0001493152-25-009737|2)

## The disclosure: institutional access at real scale (not “nice-to-have”) Scienture says it has formalized multiple Group Purchasing Organization (GPO) agreements for REZENOPY™ (naloxone HCl) Nasal Spray 10 mg that provide access to **more than 5,000** U.S. healthcare institutions, representing potential penetration of **~60% of the U.S. institutional market**, and expanding reach across hospitals/clinics/nursing homes as well as first responders, EMS providers, and rehabilitation centers. ["GPO agreements"](https://www.manilatimes.net/2026/03/11/tmt-newswire/globenewswire/scienture-broadens-commercial-access-for-rezenopy-highest-dose-fda-approved-naloxone-nasal-spray-through-gpo-agreements-reaching-over-5000-us-institutions/2297857) ["more than 5000"](https://www.manilatimes.net/2026/03/11/tmt-newswire/globenewswire/scienture-broadens-commercial-access-for-rezenopy-highest-dose-fda-approved-naloxone-nasal-spray-through-gpo-agreements-reaching-over-5000-us-institutions/2297857) ["roughly 60%"](https://www.manilatimes.net/2026/03/11/tmt-newswire/globenewswire/scienture-broadens-commercial-access-for-rezenopy-highest-dose-fda-approved-naloxone-nasal-spray-through-gpo-agreements-reaching-over-5000-us-institutions/2297857) ## The “between-the-lines” alpha: procurement gravity beats awareness marketing The real signal here is **channel control**. In institutional pharma, getting into the purchasing lane is often the gating factor; a product can have clinical rationale and still stall if it’s not in the contracting rails buyers actually use. By locking in GPO access *before* broad-scale adoption, Scienture is effectively attempting to convert REZENOPY from a “product story” into a **procurement default** across a large swath of the institutional landscape. ["Institutional procurement channels are a key driver"](https://www.manilatimes.net/2026/03/11/tmt-newswire/globenewswire/scienture-broadens-commercial-access-for-rezenopy-highest-dose-fda-approved-naloxone-nasal-spray-through-gpo-agreements-reaching-over-5000-us-institutions/2297857) ## Why this matters specifically for REZENOPY: a high-dose product positioned for hard cases The company is explicitly positioning REZENOPY as the **highest-dose FDA-approved naloxone nasal spray**, and ties the institutional push to settings where “failure is not an option” (EMS, hospitals, rehab)—i.e., environments that may value higher-dose rescue options for potent opioids. ["highest-dose FDA-approved"](https://www.manilatimes.net/2026/03/11/tmt-newswire/globenewswire/scienture-broadens-commercial-access-for-rezenopy-highest-dose-fda-approved-naloxone-nasal-spray-through-gpo-agreements-reaching-over-5000-us-institutions/2297857) ["highest dosage"](https://www.manilatimes.net/2026/03/11/tmt-newswire/globenewswire/scienture-broadens-commercial-access-for-rezenopy-highest-dose-fda-approved-naloxone-nasal-spray-through-gpo-agreements-reaching-over-5000-us-institutions/2297857) ## The de-risking angle from filings: rights + supply chain + commercial control Importantly, this institutional expansion sits on top of a structure Scienture already disclosed: an **exclusive** U.S. commercialization arrangement where Scienture has the right and license to commercialize REZENOPY in the U.S. and intends to price, launch, promote, market, and distribute the product. ["exclusive... right and license"](0001493152-25-009737|0) ["price, launch, promote"](0001493152-25-009737|0) Just as critical, the earlier disclosure also frames a cleaner execution model: Kindeva (via Summit Biosciences) manufactures and commercially supplies REZENOPY, while Scienture owns the NDA and runs sales/marketing/distribution through its commercial infrastructure—i.e., Scienture is trying to scale demand through contracting and channel access while leaning on an established partner for supply. ["manufacture and commercially supply"](0001493152-25-009737|2) ["own the new drug application"](0001493152-25-009737|2) ["sales, marketing and distribution"](0001493152-25-009737|2)